Clinical Trial Update: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) [Phase 3]

View source ↗

Summary

Clinical trial update evaluating the efficacy and safety of tildrakizumab versus placebo in active psoriatic arthritis in a Phase 3 study (INSPIRE 1). The updat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Ilumya (tildrakizumab)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Active Psoriatic Arthritis | Phase 3 | Status: COMPLETED